Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia

被引：30

作者：

Meggendorfer, Manja ^{[1
]}

de Albuquerque, Andreia ^{[1
]}

Nadarajah, Niroshan ^{[1
]}

Alpermann, Tamara ^{[1
]}

Kern, Wolfgang ^{[1
]}

Steuer, Kimberly ^{[1
]}

Perglerova, Karolna ^{[2
]}

Haferlach, Claudia ^{[1
]}

Schnittger, Susanne ^{[1
]}

Haferlach, Torsten ^{[1
]}

机构：

[1] MLL Munich Leukemia Lab, Munich, Germany

[2] MLL2 Sro, Prague, Czech Republic

来源：

HAEMATOLOGICA | 2015年 / 100卷 / 12期

关键词：

MDS; s-AML; mutation analysis; MUTATIONS; FREQUENCY; PROGNOSIS; NPM1; NRAS; MDS;

D O I：

10.3324/haematol.2015.127985

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E487 / E490

页数：4

共 50 条

[41] Rational for targeting the hedgehog signalling pathway in acute myeloid leukemia with FLT3 mutation
Bouscary, Didier
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4
[42] FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype
Ferrara, Felicetto
Criscuolo, Clelia
Riccardi, Cira
Izzo, Tiziana
Pedata, Mariangela
Copia, Carolina
Vicari, Laura
Tarsitano, Marina
Palmieri, Salvatore
Pane, Fabrizio
AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (08) : 532 - 535
[43] Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
McMahon, Christine M.
Ferng, Timothy
Canaani, Jonathan
Wang, Eunice S.
Issette, Jennifer J. D. Morr
Eastburn, Dennis J.
Pellegrino, Maurizio
Durruthy-Durruthy, Robert
Watt, Christopher D.
Asthana, Saurabh
Lasater, Elisabeth A.
DeFilippis, RosaAnna
Peretz, Cheryl A. C.
McGary, Lisa H. F.
Deihimi, Safoora
Logan, Aaron C.
Luger, Selina M.
Shah, No P.
Carroll, Martin
Smith, Catherine C.
Perl, Alexander E.
CANCER DISCOVERY, 2019, 9 (08) : 1050 - 1063
[44] FLT3 internal tandem duplication during myelodysplastic syndrome follow-up:: a marker of transformation to acute myeloid leukemia
Pinheiro, Ronald Feitosa
Moreira, Eloisa de Sa
Regis Silva, Maria Regina
Alberto, Fernando Lopes
Chauffaille, Maria de Lourdes L. F.
CANCER GENETICS AND CYTOGENETICS, 2008, 183 (02) : 89 - 93
[45] FLT3 ligand plasma levels in acute myeloid leukemia
Peterlin, Pierre
Gaschet, Joelle
Guillaume, Thierry
Garnier, Alice
Eveillard, Marion
Le Bourgeois, Amandine
Cherel, Michel
Debord, Camille
Le Bris, Yannick
Theisen, Olivier
Mahe, Beatrice
Dubruille, Viviane
Godon, Catherine
Robillard, Nelly
Wuilleme, Soraya
Touzeau, Cyrille
Gastinne, Thomas
Blin, Nicolas
Lok, Anne
Bonnet, Antoine
Le Gouill, Steven
Moreau, Philippe
Bene, Marie-C
Chevallier, Patrice
HAEMATOLOGICA, 2019, 104 (06) : E240 - E243
[46] Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia
Mattison, Ryan J.
Ostler, Kelly R.
Locke, Frederick L.
Godley, Lucy A.
REVIEWS ON RECENT CLINICAL TRIALS, 2007, 2 (02) : 135 - 141
[47] The clinical development of FLT3 inhibitors in acute myeloid leukemia
Knapper, Steven
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (10) : 1377 - 1395
[48] Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor
Paudel, Anish
Dhital, Rashmi
Areoye, Gabriel
Basnet, Sijan
Tachamo, Niranjan
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2020, 10 (03): : 275 - 278
[49] FLT3 inhibition as a targeted therapy for acute myeloid leukemia
Sanz, Miguel
Burnett, Alan
Lo-Coco, Francesco
Lowenberg, Bob
CURRENT OPINION IN ONCOLOGY, 2009, 21 (06) : 594 - 600
[50] SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
Puissant, Alexandre
Fenouille, Nina
Alexe, Gabriela
Pikman, Yana
Bassi, Christopher F.
Mehta, Swapnil
Du, Jinyan
Kazi, Julhash U.
Luciano, Frederic
Ronnstrand, Lars
Kung, Andrew L.
Aster, Jon C.
Galinsky, Ilene
Stone, Richard M.
DeAngelo, Daniel J.
Hemann, Michael T.
Stegmaier, Kimberly
CANCER CELL, 2014, 25 (02) : 226 - 242

← 1 2 3 4 5 →